You are here
The goal of the Consultation and review of the AR-DRG and ICD-10-AM/ACHI/ACS Classification Systems report was to review the end-to-end development processes, implementation arrangements and user needs in developing and implementing updates to the following classifications, now and into the future:
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions. This data plan sets out IHPA's eighth rolling Three Year Data Plan, covering the period 2020–21 to 2022–23. The Three Year Data Plan specifies the data requirements and timelines that IHPA will use to collect data over the next three years.
IHPA is responsible for relevant data collections to enable activity based funding. IHPA’s Data Access and Release Policy outlines the principles and processes adopted by IHPA in the discretionary access and release of data collected under the National Health Reform Act 2011. The Policy provides guidance as to how IHPA will determine whether to release data.
The purpose of the Management of Confidential Jurisdictional Information Protocol is to advise jurisdictions of the processes and controls adopted by IHPA in managing confidential jurisdictional information as part of its rolling Three Year Data Plan.
Each year, IHPA publishes the General List of In-Scope Public Hospital Services (the General List) as part of the National Efficient Price Determination.
The General List defines public hospital services eligible for Commonwealth funding, except where funding is otherwise agreed between the Commonwealth and a state or territory.